David A. Siegel Profound Medical Corp. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.38 - $15.2 $155,700 - $228,000	-15,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.6 - $17.88 $204,000 - $268,200	-15,000 Reduced 50.0%	15,000 $220,000
Q2 2021 Aug 16, 2021	SELL	$16.0 - $20.59 $283,200 - $364,443	-17,700 Reduced 37.11%	30,000 $491,000
Q1 2021 May 17, 2021	BUY	$19.16 - $28.09 $103,464 - $151,686	5,400 Added 12.77%	47,700 $961,000
Q4 2020 Feb 16, 2021	BUY	$16.4 - $22.9 $188,599 - $263,350	11,500 Added 37.34%	42,300 $870,000
Q3 2020 Nov 16, 2020	BUY	$14.05 - $18.13 $160,170 - $206,682	11,400 Added 58.76%	30,800 $543,000
Q2 2020 Aug 14, 2020	BUY	$9.41 - $16.94 $182,554 - $328,636	19,400 New	19,400 $329,000

8.93M

1.2K

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $157M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.